Alterity Therapeutics Initiates Second Phase 2 Study In Rare Parkinsonian Disorder
Portfolio Pulse from Benzinga Newsdesk
Alterity Therapeutics has initiated a second Phase 2 study for its drug candidate ATH434 in the treatment of Multiple System Atrophy (MSA), a rare Parkinsonian disorder. The study aims to evaluate the safety, tolerability, and efficacy of the drug.
May 30, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alterity Therapeutics has started a second Phase 2 study for ATH434, targeting the treatment of Multiple System Atrophy. This could potentially lead to positive outcomes for the company.
The initiation of a second Phase 2 study for ATH434 indicates progress in the drug's development. If the study yields positive results, it could lead to increased investor interest and a potential rise in ATHE's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100